Pharmacokinetic (PK) analysis of fluticasone furoate (FF), umeclidinium (UMEC) and vilanterol (VI) following triple therapy at two UMEC doses in healthy subjects

被引：0
|
作者：
Henderson, A.
Allen, A.
Gupta, A.
Renaux, J.
Brealey, N.
机构：
来源：
EUROPEAN RESPIRATORY JOURNAL | 2014年 / 44卷
关键词：
Bronchodilators; COPD; -; management; Pharmacology;
D O I：
暂无
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
P938
引用
收藏
页数：5
相关论文
共 50 条
  • [41] The IMPACT Trial: Single Inhaler Triple Therapy Fluticasone Furoate/Umeclidinium/Vilanterol versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients with COPD: A Pre-Specified Analysis of Safety According to Age
    Criner, G. J.
    Dransfield, M.
    Halpin, D. M. G.
    Han, M. K.
    Jones, C. E.
    Kilbride, S.
    Lange, P.
    Lomas, D. A.
    Martinez, F.
    Pascoe, S.
    Singh, D.
    Wise, R.
    Lipson, D. A.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [42] In-vitro product performance of fluticasone furoate (FF)/umeclidinium (UMEC)/vilanterol (VI) delivered from a dry powder inhaler (DPI) using the Electronic Lung (EL) to replicate patient inhalation profiles
    Prime, David
    Hamilton, Melanie
    Taylor, Edward
    EUROPEAN RESPIRATORY JOURNAL, 2019, 54
  • [43] Pharmacokinetics of fluticasone furoate, umeclidinium, and vilanterol as a triple therapy in healthy volunteers (vol 53, pg 753, 2015)
    Brealey, Noushin
    Gupta, Ashutosh
    Renaux, Jessica
    Mehta, Rashmi
    Allen, Ann
    Henderson, Alex
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2016, 54 (01) : 76 - 80
  • [44] Reduction in All-Cause Mortality with Single Inhaler Triple Therapy (FF/UMEC/VI) Versus Dual Therapy (FF/VI and UMEC/VI) in Symptomatic Patients with COPD: Prespecified Analysis of the Phase III IMPACT Trial
    Lipson, D. A.
    Barnhart, F.
    Brealey, N.
    Day, N. C.
    Brooks, J.
    Criner, G.
    Dransfield, M. T.
    Halpin, D. M.
    Han, M. K.
    Jones, C.
    Kilbride, S.
    Lange, P.
    Lomas, D. A.
    Martinez, F. J.
    Singh, D.
    Tabberer, M.
    Wise, R. A.
    Pascoe, S. J.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
  • [45] InforMing the PAthway of COPD Treatment (The IMPACT Study): Single Inhaler Triple Therapy (Fluticasone Furoate/Umeclidinium/Vilanterol) Versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients With COPD: An Analysis Based on Baseline COPD Medication Use
    Singh, D.
    Criner, G. J.
    Dransfield, M. T.
    Halpin, D. M. G.
    Han, M. K.
    Jones, C. E.
    Kilbride, S.
    Lange, P.
    Lomas, D. A.
    Martinez, F. J.
    Pascoe, S. J.
    Wise, R. A.
    Lipson, D. A.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [46] InforMing the PAthway of COPD Treatment (IMPACT Study)-Single Inhaler Triple Therapy (Fluticasone Furoate/Umeclidinium/Vilanterol) Versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients with COPD: Results Based on an Analysis of the North American Region
    Wise, R. A.
    Criner, G. J.
    Dransfield, M. T.
    Han, M. K.
    Jones, C. E.
    Lettis, S.
    Martinez, F. J.
    Pascoe, S. J.
    Quasny, H.
    Lipson, D. A.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [47] Captain Study: Evaluating the Efficacy of Once-Daily, Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus FF/VI in Inadequately Controlled Asthma Using Change in Asthma Control Questionnaire and the Relationship with Trough FEV1
    Fowler, A.
    Kerstjens, H.
    Bailes, Z.
    Tabberer, M.
    Barnes, N.
    Peachey, G.
    Oppenheimer, J.
    Lee, L.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [48] InforMing the PAthway of COPD Treatment (IMPACT Trial) Single-Inhaler Triple Therapy (Fluticasone Furoate/Umeclidinium/Vilanterol) Versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients With COPD: Analysis o the Western Europe and North America Regions
    Bourdin, Arnaud
    Criner, Gerard
    Devouassoux, Gilles
    Dransfield, Mark
    Halpin, David M. G.
    Han, MeiLan K.
    Jones, C. Elaine
    Kalhan, Ravi
    Lange, Peter
    Lettis, Sally
    Lipson, David A.
    Lomas, David A.
    Maria-Tome, Jose M. Echave-Sustaeta
    Martin, Neil
    Martinez, Fernando J.
    Quasny, Holly
    Sail, Lynda
    Siler, Thomas M.
    Singh, Dave
    Thomashow, Byron
    Watz, Henrik
    Wise, Robert
    Hanania, Nicola A.
    CHRONIC OBSTRUCTIVE PULMONARY DISEASES-JOURNAL OF THE COPD FOUNDATION, 2021, 8 (01): : 76 - 90
  • [49] Cost-effectiveness of Budesonide/Glycopyrrolate/Formoterol Fumarate (BGF) Versus Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) to Treat COPD Based on Mortality Risk Reduction From a Matching-adjusted Indirect Treatment Comparison
    Parsekar, K.
    Pandey, S.
    Tansey-Dwyer, D.
    Marshall, J.
    Rustignoli, I.
    Pollack, M.
    Singh, B.
    Ouwens, M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209
  • [50] The efficacy and safety of Fluticasone Furoate/Umeclidinium/vilanterol (FF/UMEC/VI) on cough symptoms in adult patients with asthma, a randomized double-blind, placebo-controlled, parallel group study: Chronic Cough in Asthma (COCOA) study
    Tagaya, Etsuko
    Shinada, Jun
    Nagase, Hiroyuki
    Terada-Hirashima, Junko
    Hojo, Masayuki
    Sugihara, Naruhiko
    Yagi, Osamitsu
    Tsuji, Mayoko
    Akaba, Tomohiro
    Masaki, Katsunori
    Fukunaga, Koichi
    Ohbayashi, Hiroyuki
    Chiba, Kaoru
    Hozawa, Soichiro
    Atsuta, Ryo
    Aoki, Yasuhiro
    Hiranuma, Hisato
    Gon, Yasuhiro
    Tanaka, Akihiko
    JOURNAL OF ASTHMA, 2025,
12345